What is Mounjaro made from, and how does it work?

What kind of molecule is tirzepatide, exactly?

Tirzepatide is a 39-amino-acid synthetic peptide. Researchers at Eli Lilly built it by studying the structures of GIP and GLP-1, two hormones the gut releases after eating, and then designing a single molecule capable of docking with both their receptors. The result is sometimes described as a "dual agonist" because it activates (agonises) both pathways at once.

Natural GIP and GLP-1 break down in the body within minutes. To make tirzepatide viable as a once-weekly injection, Lilly attached a fatty-acid chain to the peptide backbone. That attachment binds loosely to albumin, a protein already present in your blood, which slows the molecule's clearance and keeps it active for roughly seven days. It's elegant chemistry, the fatty-acid trick is the same broad approach used in long-acting insulins.

The inactive ingredients in the pen solution include sodium phosphate, mannitol, polysorbate 80 and water for injections. These are standard pharmaceutical excipients: buffers, stabilisers and a wetting agent that keep the peptide stable during storage. If you have known allergies to any component, that conversation belongs with a prescriber before treatment starts. The tirzepatide overview page covers the licensed indications and eligibility criteria in full.

Why does it target GIP as well as GLP-1?

Most people who follow weight-loss medicine news have heard of GLP-1 agonists, semaglutide is the most familiar example. GLP-1 signalling reduces appetite and slows gastric emptying. Targeting it alone produces meaningful results. So why add GIP?

GIP receptors are found in fat tissue as well as the pancreas. Activating them alongside GLP-1 appears to amplify the appetite-reduction effect and may improve how the body handles dietary fat, though researchers are still mapping the precise mechanisms. What the clinical evidence shows is that the combination produces greater average weight loss than GLP-1 alone at comparable doses. In the SURMOUNT-1 trial, involving more than 2,500 adults with obesity, participants receiving tirzepatide 15 mg lost an average of around 20–21% of their body weight over 72 weeks, figures cited by NICE's appraisal of tirzepatide (TA1026) when weighing the evidence. These are trial averages; individual outcomes vary, and no treatment guarantees a specific result.

The dual-receptor design is also why tirzepatide is formally categorised differently from semaglutide in clinical literature. For a side-by-side look at what tirzepatide is made of compared with other GLP-1 medicines, that page goes into the molecular distinctions.

Does what Mounjaro is made from affect its side-effect profile?

The short answer is yes, in the sense that the molecule's mechanism drives most of what patients experience. Because tirzepatide slows gastric emptying and acts on appetite centres, the most common side effects are gastrointestinal: nausea, loose stools, constipation, bloating and reflux feature most often. These tend to be most noticeable shortly after a dose increase and usually settle within a week or two as the body adjusts. Fatigue, headache and injection-site reactions are also reported.

The NHS patient information page for tirzepatide lists the full side-effect profile clearly and is a good first read alongside the patient information leaflet that comes with every pen. Rare but serious effects (including pancreatitis symptoms such as severe stomach pain that radiates to the back) require prompt medical attention. Yellow Card reporting at the MHRA is available to anyone who suspects a side effect they want flagged.

Because the molecule binds to receptors involved in gastric motility, it can slow the absorption of other oral medicines taken around the same time. For women on the combined oral contraceptive pill, clinical guidance recommends adding a barrier method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase; the Mounjaro information page touches on this and other prescriber-review points. The cost of Mounjaro treatment (including what a legitimate private prescription involves) is covered separately if that's your next question.

Is the tirzepatide in Mounjaro pens genuine pharmaceutical-grade material?

This question comes up more than you might expect, and it's worth addressing plainly. The counterfeit market for injectable weight-loss medicines in the UK is real and documented. The MHRA has raided UK manufacturing sites producing fake tirzepatide pens and seized around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million, a scale that reflects serious organised activity, not isolated incidents.

Genuine Mounjaro is supplied through the licensed UK pharmaceutical supply chain, sourced from Eli Lilly's authorised distributors. If you want to understand what tirzepatide is made from and how it is manufactured to pharmaceutical grade, that page explains the production standards behind the authentic medicine. At nume, medicines come through that licensed chain, dispensed from our GPhC-registered pharmacy (registration number 9012878, verifiable at the GPhC online register). Any seller offering tirzepatide without requiring a prescription, via social media, or at prices far below the established market range is a red flag worth taking seriously. Fake pens have been found to contain insulin rather than tirzepatide, the consequences can be severe. Sourcing from a regulated, verifiable pharmacy is not a minor detail.

If you'd like to explore whether Mounjaro treatment might suit your circumstances, speaking to our prescribers through a free consultation is the place to start. There's no pressure and no commitment, a real clinician reads your answers the same day.